346 related articles for article (PubMed ID: 24042261)
1. Antidiabetic medications and the risk of colorectal cancer in patients with diabetes mellitus: a systematic review and meta-analysis.
Singh S; Singh H; Singh PP; Murad MH; Limburg PJ
Cancer Epidemiol Biomarkers Prev; 2013 Dec; 22(12):2258-68. PubMed ID: 24042261
[TBL] [Abstract][Full Text] [Related]
2. Anti-diabetic medications and the risk of hepatocellular cancer: a systematic review and meta-analysis.
Singh S; Singh PP; Singh AG; Murad MH; Sanchez W
Am J Gastroenterol; 2013 Jun; 108(6):881-91; quiz 892. PubMed ID: 23381014
[TBL] [Abstract][Full Text] [Related]
3. Anti-diabetic medications and risk of pancreatic cancer in patients with diabetes mellitus: a systematic review and meta-analysis.
Singh S; Singh PP; Singh AG; Murad MH; McWilliams RR; Chari ST
Am J Gastroenterol; 2013 Apr; 108(4):510-9; quiz 520. PubMed ID: 23399556
[TBL] [Abstract][Full Text] [Related]
4. Anti-diabetic medications do not influence risk of lung cancer in patients with diabetes mellitus: a systematic review and meta-analysis.
Nie SP; Chen H; Zhuang MQ; Lu M
Asian Pac J Cancer Prev; 2014; 15(16):6863-9. PubMed ID: 25169538
[TBL] [Abstract][Full Text] [Related]
5. Thiazolidinediones and risk of colorectal cancer in patients with diabetes mellitus: A meta-analysis.
Liu Y; Jin PP; Sun XC; Hu TT
Saudi J Gastroenterol; 2018; 24(2):75-81. PubMed ID: 29637913
[TBL] [Abstract][Full Text] [Related]
6. Antidiabetic Medications and the Risk of Endometrial Cancer in Patients.
Tian J; Liang Y; Qu P
Gynecol Obstet Invest; 2019; 84(5):455-462. PubMed ID: 30808843
[TBL] [Abstract][Full Text] [Related]
7. Pharmacologic Therapy of Diabetes and Overall Cancer Risk and Mortality: A Meta-Analysis of 265 Studies.
Wu L; Zhu J; Prokop LJ; Murad MH
Sci Rep; 2015 Jun; 5():10147. PubMed ID: 26076034
[TBL] [Abstract][Full Text] [Related]
8. Use of metformin is not associated with a decreased risk of colorectal cancer: a case-control analysis.
Bodmer M; Becker C; Meier C; Jick SS; Meier CR
Cancer Epidemiol Biomarkers Prev; 2012 Feb; 21(2):280-6. PubMed ID: 22178569
[TBL] [Abstract][Full Text] [Related]
9. Antidiabetic medications and the risk of prostate cancer in patients with diabetes mellitus: A systematic review and meta-analysis.
Cui H; Wang Y; Yang S; He G; Jiang Z; Gang X; Wang G
Pharmacol Res; 2022 Mar; 177():106094. PubMed ID: 35074527
[TBL] [Abstract][Full Text] [Related]
10. Reduced risk of colorectal cancer with metformin therapy in patients with type 2 diabetes: a meta-analysis.
Zhang ZJ; Zheng ZJ; Kan H; Song Y; Cui W; Zhao G; Kip KE
Diabetes Care; 2011 Oct; 34(10):2323-8. PubMed ID: 21949223
[TBL] [Abstract][Full Text] [Related]
11. Relationship between metformin therapy and risk of colorectal cancer in patients with diabetes mellitus: a meta-analysis.
Yang WT; Yang HJ; Zhou JG; Liu JL
Int J Colorectal Dis; 2020 Nov; 35(11):2117-2131. PubMed ID: 32720184
[TBL] [Abstract][Full Text] [Related]
12. Effect of metformin use on the risk and prognosis of colorectal cancer in diabetes mellitus: a meta-analysis.
Wang Q; Shi M
Anticancer Drugs; 2022 Feb; 33(2):191-199. PubMed ID: 34620743
[TBL] [Abstract][Full Text] [Related]
13. Thiazolidinedione use and cancer incidence in type 2 diabetes: a systematic review and meta-analysis.
Colmers IN; Bowker SL; Johnson JA
Diabetes Metab; 2012 Dec; 38(6):475-84. PubMed ID: 23041441
[TBL] [Abstract][Full Text] [Related]
14. The use of metformin and colorectal cancer incidence in patients with type II diabetes mellitus.
Smiechowski B; Azoulay L; Yin H; Pollak MN; Suissa S
Cancer Epidemiol Biomarkers Prev; 2013 Oct; 22(10):1877-83. PubMed ID: 23966577
[TBL] [Abstract][Full Text] [Related]
15. Metformin therapy and risk of colorectal adenomas and colorectal cancer in type 2 diabetes mellitus patients: A systematic review and meta-analysis.
Liu F; Yan L; Wang Z; Lu Y; Chu Y; Li X; Liu Y; Rui D; Nie S; Xiang H
Oncotarget; 2017 Feb; 8(9):16017-16026. PubMed ID: 27926481
[TBL] [Abstract][Full Text] [Related]
16. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
17. Are sulfonylurea and insulin therapies associated with a larger risk of cancer than metformin therapy? A retrospective database analysis.
Kowall B; Rathmann W; Kostev K
Diabetes Care; 2015 Jan; 38(1):59-65. PubMed ID: 25336750
[TBL] [Abstract][Full Text] [Related]
18. Anti-diabetic medications and the risk for colorectal cancer: A population-based nested case-control study.
Shin CM; Kim N; Han K; Kim B; Jung JH; Oh TJ; Lee DH
Cancer Epidemiol; 2020 Feb; 64():101658. PubMed ID: 31887708
[TBL] [Abstract][Full Text] [Related]
19. Metformin, Diabetes, and Survival among U.S. Veterans with Colorectal Cancer.
Paulus JK; Williams CD; Cossor FI; Kelley MJ; Martell RE
Cancer Epidemiol Biomarkers Prev; 2016 Oct; 25(10):1418-1425. PubMed ID: 27496094
[TBL] [Abstract][Full Text] [Related]
20. Initial metformin or sulphonylurea exposure and cancer occurrence among patients with type 2 diabetes mellitus.
Qiu H; Rhoads GG; Berlin JA; Marcella SW; Demissie K
Diabetes Obes Metab; 2013 Apr; 15(4):349-57. PubMed ID: 23137378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
